Intensity Therapeutics, Inc. (INTS)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Intensity Therapeutics, Inc. (INTS) trades at $5.93 with AI Score 45/100 (Weak). Intensity Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative cancer drugs. Market cap: 16M, Sector: Healthcare.
Last analyzed: Feb 8, 2026Intensity Therapeutics, Inc. (INTS) Healthcare & Pipeline Overview
Intensity Therapeutics (INTS) is pioneering a novel approach to cancer treatment with INT230-6, a promising drug in Phase 2 trials targeting refractory solid tumors. Collaborations with Merck and Bristol-Myers Squibb enhance its potential, positioning INTS as a compelling investment in the biotechnology sector.
Investment Thesis
Intensity Therapeutics presents a notable research candidate within the biotechnology sector. The company's lead product candidate, INT230-6, is currently in Phase 2 clinical trials, targeting a wide array of solid tumors. Positive trial results could serve as a significant catalyst, driving substantial value appreciation. The company's strategic collaborations with industry giants like Merck and Bristol-Myers Squibb validate the potential of INT230-6 and provide non-dilutive funding opportunities. With a market capitalization of $0.02 billion, INTS offers significant upside potential if INT230-6 demonstrates efficacy and secures regulatory approval. The high beta of 4.22 suggests a volatile stock, but also the potential for outsized gains. Investment is predicated on successful clinical trial outcomes and continued partnership momentum.
Based on FMP financials and quantitative analysis
Key Highlights
- INT230-6 is in Phase 2 clinical trials, targeting a broad range of solid tumors including pancreatic, colon, breast and liver cancers.
- Collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate INT230-6 in combination with Keytruda.
- Collaboration agreement with Bristol-Myers Squibb Company to evaluate INT230-6 in combination with Yervoy.
- Market capitalization of $0.02 billion indicates a small-cap company with potential for high growth.
- Beta of 4.22 suggests high volatility, indicating potential for significant gains or losses.
Competitors & Peers
Strengths
- Novel drug candidate (INT230-6) in Phase 2 trials.
- Strategic collaborations with Merck and Bristol-Myers Squibb.
- Focus on a broad range of solid tumors.
- Strong intellectual property protection.
Weaknesses
- Limited financial resources.
- Small number of employees.
- Reliance on a single lead product candidate.
- High risk of clinical trial failure.
Catalysts
- Upcoming: Completion of Phase 2 clinical trials for INT230-6.
- Upcoming: Data readout from ongoing clinical trials in pancreatic, colon, breast, and liver cancers.
- Ongoing: Potential for new strategic partnerships and licensing agreements.
- Ongoing: Advancement of pipeline candidates through preclinical and clinical development.
Risks
- Potential: Clinical trial failures for INT230-6.
- Potential: Regulatory delays or rejection of drug approval.
- Ongoing: Competition from other biotechnology and pharmaceutical companies.
- Ongoing: Difficulty in raising capital to fund operations.
- Potential: Dependence on collaborations with Merck and Bristol-Myers Squibb.
Growth Opportunities
- Expansion of INT230-6 Clinical Trials: Intensity Therapeutics has the opportunity to expand the clinical trials for INT230-6 to include additional cancer types and patient populations. The global solid tumor market is projected to reach $476 billion by 2028, presenting a significant market opportunity. Positive results from these expanded trials could lead to accelerated regulatory approval and commercialization, driving revenue growth. This expansion is ongoing as of February 8, 2026.
- Strategic Partnerships and Licensing Agreements: The company can pursue additional strategic partnerships and licensing agreements with larger pharmaceutical companies to further develop and commercialize INT230-6. These partnerships can provide access to additional funding, expertise, and distribution channels. The timeline for securing new partnerships is dependent on clinical trial progress and market interest, but represents an ongoing opportunity.
- Advancement of Pipeline Candidates: Intensity Therapeutics can focus on advancing its earlier-stage pipeline candidates through preclinical and clinical development. This would diversify the company's product portfolio and reduce its reliance on INT230-6. The development timeline for these candidates is several years, but successful advancement could create long-term value.
- Acquisition or Merger Opportunities: Intensity Therapeutics could explore potential acquisition or merger opportunities with other biotechnology companies to expand its product portfolio, access new technologies, or achieve economies of scale. The timing of such opportunities is uncertain, but could provide a significant boost to the company's growth prospects.
- Orphan Drug Designation: Pursuing orphan drug designation for INT230-6 in specific rare cancer subtypes could provide market exclusivity and other regulatory benefits. The timeline for obtaining orphan drug designation depends on the specific cancer subtype and regulatory review process, but could provide a competitive advantage upon approval.
Opportunities
- Expansion of clinical trials to new cancer types.
- Securing additional partnerships and licensing agreements.
- Advancement of pipeline candidates.
- Potential for orphan drug designation.
Threats
- Competition from established pharmaceutical companies.
- Regulatory hurdles and delays.
- Clinical trial failures.
- Difficulty in raising capital.
Competitive Advantages
- Proprietary drug formulation (INT230-6).
- Strategic collaborations with major pharmaceutical companies.
- Patent protection for its drug candidates.
- Clinical trial data demonstrating efficacy.
About INTS
Founded in 2012 and headquartered in Westport, Connecticut, Intensity Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization of cancer drugs designed to treat solid tumors. The company's core focus revolves around its lead product candidate, INT230-6, which is currently undergoing Phase 2 clinical trials. This innovative drug is being evaluated for its efficacy in treating a range of refractory solid tumors, including cancers of the pancreas, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver. Intensity Therapeutics has strategically established collaboration agreements with leading pharmaceutical companies to broaden the evaluation and potential application of INT230-6. A collaboration with Merck Sharpe & Dohme Corp. is underway to assess the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies. Additionally, a partnership with Bristol-Myers Squibb Company aims to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers. The company is also collaborating with the Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer. These collaborations underscore the potential of INT230-6 and the company's commitment to advancing cancer treatment.
What They Do
- Develops cancer drugs to treat solid tumors.
- Conducts Phase 2 clinical trials for INT230-6.
- Targets refractory solid tumors including pancreatic, colon, and breast cancers.
- Collaborates with Merck to evaluate INT230-6 with Keytruda.
- Collaborates with Bristol-Myers Squibb to evaluate INT230-6 with Yervoy.
- Partners with research institutes to study INT230-6 in breast cancer.
Business Model
- Develops and patents novel cancer drugs.
- Conducts clinical trials to demonstrate safety and efficacy.
- Partners with pharmaceutical companies for co-development and commercialization.
- Seeks regulatory approval for its drug candidates.
Industry Context
Intensity Therapeutics operates within the competitive biotechnology industry, which is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. The market for cancer therapeutics is substantial and growing, driven by an aging population and increasing cancer incidence rates. Intensity Therapeutics is focused on solid tumors, a significant segment of the oncology market. Competitors like ANTX, BOLD, IBIO, ITRM, and NXTC are also vying for market share in this space. Success in this industry requires innovative technologies, strong clinical trial results, and strategic partnerships.
Key Customers
- Patients with solid tumors.
- Hospitals and oncology clinics.
- Pharmaceutical companies through collaborations.
- Research institutions for clinical trials.
Financials
Chart & Info
Intensity Therapeutics, Inc. (INTS) stock price: $5.93 (-0.17, -2.79%)
Latest News
-
Intensity Therapeutics Issued New U.S. Patent Entitled 'A Method of Treating Cancer'
benzinga · Mar 24, 2026
-
Intensity Therapeutics Strengthens IP Portfolio with Issuance of New Patent in the US
prnewswire.com · Mar 24, 2026
-
Intensity Therapeutics Expands ATM Offering Capacity To $60M; May Issue Up To $60M Of Common Stock Under Offering Agreement
benzinga · Mar 23, 2026
-
Intensity Therapeutics Provides Update On Phase 2 Presurgical Breast Cancer INVINCIBLE-4 Study; 71.4% Of Patients Who Received INT230-6 Prior To Standard Of Care Achieved A Pathological Complete Response
benzinga · Mar 12, 2026
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for INTS.
Price Targets
Wall Street price target analysis for INTS.
MoonshotScore
What does this score mean?
The MoonshotScore rates INTS's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Latest News
Intensity Therapeutics Issued New U.S. Patent Entitled 'A Method of Treating Cancer'
Intensity Therapeutics Strengthens IP Portfolio with Issuance of New Patent in the US
Intensity Therapeutics Expands ATM Offering Capacity To $60M; May Issue Up To $60M Of Common Stock Under Offering Agreement
Intensity Therapeutics Provides Update On Phase 2 Presurgical Breast Cancer INVINCIBLE-4 Study; 71.4% Of Patients Who Received INT230-6 Prior To Standard Of Care Achieved A Pathological Complete Response
INTS Healthcare Stock FAQ
What does Intensity Therapeutics, Inc. do?
Intensity Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative cancer drugs for the treatment of solid tumors. Their primary focus is on INT230-6, a drug candidate currently in Phase 2 clinical trials. This drug is being evaluated for its effectiveness against a variety of solid tumors, including cancers of the pancreas, colon, breast, and liver. The company operates through strategic collaborations with major pharmaceutical companies and research institutions to advance its drug development programs.
Is INTS stock worth researching?
Investing in INTS stock carries significant risk due to its clinical-stage nature and reliance on the success of INT230-6. The company's market capitalization is $0.02 billion, reflecting its small size and speculative nature. Positive results from ongoing Phase 2 clinical trials could drive significant upside, but failure to meet endpoints or regulatory hurdles could lead to substantial losses. The high beta of 4.22 indicates high volatility. Investors should carefully consider their risk tolerance and conduct thorough due diligence before investing.
What are the main risks for INTS?
The primary risks for Intensity Therapeutics include the potential failure of INT230-6 in clinical trials, which would significantly impact the company's value. Regulatory hurdles and delays in obtaining drug approval also pose a significant risk. Competition from larger pharmaceutical companies with more resources and established products is another concern. Additionally, the company's limited financial resources and reliance on collaborations for funding create financial and operational risks. These factors contribute to the speculative nature of INTS stock.
What are the key factors to evaluate for INTS?
Intensity Therapeutics, Inc. (INTS) currently holds an AI score of 45/100, indicating low score. Key strength: Novel drug candidate (INT230-6) in Phase 2 trials.. Primary risk to monitor: Potential: Clinical trial failures for INT230-6.. This is not financial advice.
How frequently does INTS data refresh on this page?
INTS prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven INTS's recent stock price performance?
Recent price movement in Intensity Therapeutics, Inc. (INTS) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Novel drug candidate (INT230-6) in Phase 2 trials.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider INTS overvalued or undervalued right now?
Determining whether Intensity Therapeutics, Inc. (INTS) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying INTS?
Before investing in Intensity Therapeutics, Inc. (INTS), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change. Investment decisions should be based on individual risk tolerance and thorough due diligence.